DK1341531T3 - Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese - Google Patents

Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese

Info

Publication number
DK1341531T3
DK1341531T3 DK01989070T DK01989070T DK1341531T3 DK 1341531 T3 DK1341531 T3 DK 1341531T3 DK 01989070 T DK01989070 T DK 01989070T DK 01989070 T DK01989070 T DK 01989070T DK 1341531 T3 DK1341531 T3 DK 1341531T3
Authority
DK
Denmark
Prior art keywords
inhibition
beta
synthesis
amyloid peptide
lactam compounds
Prior art date
Application number
DK01989070T
Other languages
Danish (da)
English (en)
Inventor
Varghese John
James Edmund Audia
Eugene D Thorsett
Lee H Latimer
Stacey Leigh Mcdaniel
Jeffrey Scott Nissen
Jay S Tung
Original Assignee
Lilly Co Eli
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Elan Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1341531T3 publication Critical patent/DK1341531T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01989070T 2000-11-17 2001-11-05 Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese DK1341531T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (fr) 2000-11-17 2001-11-05 Composé de lactam

Publications (1)

Publication Number Publication Date
DK1341531T3 true DK1341531T3 (da) 2007-05-14

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989070T DK1341531T3 (da) 2000-11-17 2001-11-05 Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese

Country Status (34)

Country Link
US (1) US20050261495A1 (fr)
EP (1) EP1341531B1 (fr)
JP (1) JP4116437B2 (fr)
KR (1) KR100819679B1 (fr)
CN (1) CN1486184A (fr)
AR (1) AR035927A1 (fr)
AU (2) AU2002243192B2 (fr)
BR (1) BR0115427A (fr)
CA (1) CA2427227C (fr)
CY (1) CY1106366T1 (fr)
CZ (1) CZ20031351A3 (fr)
DE (1) DE60126132T2 (fr)
DK (1) DK1341531T3 (fr)
DZ (1) DZ3453A1 (fr)
EA (1) EA005954B1 (fr)
EC (1) ECSP034600A (fr)
ES (1) ES2278804T3 (fr)
HK (1) HK1059731A1 (fr)
HR (1) HRP20030383B1 (fr)
HU (1) HU228117B1 (fr)
IL (2) IL155960A0 (fr)
MX (1) MXPA03004292A (fr)
MY (1) MY134559A (fr)
NO (1) NO324324B1 (fr)
NZ (1) NZ525854A (fr)
PE (1) PE20020802A1 (fr)
PL (1) PL212199B1 (fr)
PT (1) PT1341531E (fr)
SI (1) SI1341531T1 (fr)
SK (1) SK288065B6 (fr)
TW (1) TWI305204B (fr)
UA (1) UA74849C2 (fr)
WO (1) WO2002047671A2 (fr)
ZA (1) ZA200303789B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
AU2006234441B2 (en) 2005-04-08 2011-07-07 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
EP1888050B1 (fr) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
US20090023801A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
WO2009023453A1 (fr) 2007-08-14 2009-02-19 Eli Lilly And Company Dérivés d'azépine en tant qu'inhibiteurs de gamma-sécrétase
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
CN104188971B (zh) 2007-12-21 2017-05-03 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (fr) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012040444A2 (fr) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Traitement de patients présentant un début de maladie d'alzheimer
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CA2883896C (fr) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
CA2892361A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015108988A2 (fr) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Méthodes et compositions pour moduler les taux d'hormone
WO2016069906A1 (fr) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019148067A1 (fr) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Traitement de la perte auditive
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
MX2022007535A (es) 2019-12-17 2022-09-23 Merck Sharp & Dohme Llc Inhibidores de prmt5.
WO2024049931A1 (fr) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Compositions pharmaceutiques à base d'inhibiteurs de la topoisomérase-1 dérivés de l'exatécan, et leurs utilisations
WO2024091437A1 (fr) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Charges utiles de lieur adc dérivées d'exatécan, compositions pharmaceutiques et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069654A (ko) * 1996-12-23 2000-11-25 엘란 파마슈티칼스, 인크. 시클로알킬, 락탐, 락톤 및 관련 화합물, 그의 약제학적 조성물및 그를 사용한 β-아밀로이드 펩티드의 방출 및(또는) 합성억제 방법
WO1999067219A1 (fr) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2311561T3 (es) * 2000-11-17 2009-02-16 Eli Lilly And Company Dipeptido de lactama y su uso en la inhibicion de la liberacion del peptido beta amiloide.

Also Published As

Publication number Publication date
BR0115427A (pt) 2003-10-07
EA005954B1 (ru) 2005-08-25
HU228117B1 (en) 2012-11-28
PE20020802A1 (es) 2002-09-10
EA200300580A1 (ru) 2003-10-30
DZ3453A1 (fr) 2002-06-20
ES2278804T3 (es) 2007-08-16
HUP0301842A2 (hu) 2003-09-29
NO324324B1 (no) 2007-09-24
IL155960A0 (en) 2003-12-23
PT1341531E (pt) 2007-04-30
ZA200303789B (en) 2004-08-16
CA2427227A1 (fr) 2002-06-20
KR20030051846A (ko) 2003-06-25
HUP0301842A3 (en) 2010-03-29
ECSP034600A (es) 2003-06-25
HRP20030383A2 (en) 2005-10-31
SK5592003A3 (en) 2003-12-02
HRP20030383B1 (en) 2007-12-31
US20050261495A1 (en) 2005-11-24
CZ20031351A3 (cs) 2003-11-12
PL212199B1 (pl) 2012-08-31
NO20032236L (no) 2003-07-10
WO2002047671A2 (fr) 2002-06-20
CY1106366T1 (el) 2011-10-12
WO2002047671A3 (fr) 2003-03-06
EP1341531B1 (fr) 2007-01-17
UA74849C2 (en) 2006-02-15
JP2004517090A (ja) 2004-06-10
IL155960A (en) 2009-06-15
DE60126132D1 (de) 2007-03-08
AU4319202A (en) 2002-06-24
AR035927A1 (es) 2004-07-28
AU2002243192B2 (en) 2006-07-20
DE60126132T2 (de) 2007-10-18
MY134559A (en) 2007-12-31
CA2427227C (fr) 2010-08-17
TWI305204B (en) 2009-01-11
HK1059731A1 (en) 2004-07-16
MXPA03004292A (es) 2004-02-12
PL362688A1 (en) 2004-11-02
NO20032236D0 (no) 2003-05-16
JP4116437B2 (ja) 2008-07-09
EP1341531A2 (fr) 2003-09-10
SK288065B6 (sk) 2013-04-03
NZ525854A (en) 2004-06-25
CN1486184A (zh) 2004-03-31
KR100819679B1 (ko) 2008-04-04
SI1341531T1 (sl) 2007-06-30

Similar Documents

Publication Publication Date Title
DK1341531T3 (da) Lactamforbindelser til inhibering af beta-amyloidpeptidfrigivelse eller - syntese
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1181272T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1181713T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK0824631T3 (da) Fremgangsmåde til inhibering af tilstopning af ledninger med gashydrater
AR028280A1 (es) Derivados de 2-amino-3-(alquil)-pirimidona
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
DK0971920T3 (da) Forbindelser til inhibition af mavesyresekretion
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
EP1326647A4 (fr) Composes photosensibles destines a determiner instantanement la fonction d'un organe
AR027907A1 (es) Composicion de liberacion controlada
DK1204429T3 (da) Præparat til forsinket frigivelse af et peptid
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1291356T3 (da) Fremgangsmåde til hurtig oplösningssyntese af peptider
ATE362919T1 (de) Lactamverbindungen
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1206462T3 (da) Hererocykliske forbindelser til inhibering af angiogenese
AR028070A1 (es) Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin